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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
Yestimun
®
 and defence against pathogens in the upper respiratory tract 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Leiber GmbH, submitted for authorisation of a health claim pursuant to Article 
13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the Panel on Dietetic 
Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a 
health claim related to Yestimun
®
 and defence against pathogens in the upper respiratory tract. The food that is 
the subject of the health claim, Yestimun
®
, which consists of (1,3)-(1,6)-β-D-glucans from brewer’s yeast cell 
wall, is sufficiently characterised. The claimed effect, defence against pathogens in the upper respiratory tract, is 
a beneficial physiological effect. No human intervention studies from which conclusions could be drawn for the 
scientific substantiation of the claim were provided by the applicant. The Panel concludes that a cause and effect 
relationship has not been established between the consumption of Yestimun
®
 ((1,3)-(1,6)-β-D-glucans from 
brewer’s yeast cell wall) and defence against pathogens in the upper respiratory tract. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following an application from Leiber GmbH, submitted for authorisation of a health claim pursuant 
to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on 
the scientific substantiation of a health claim related to Yestimun
®
 and defence against pathogens in 
the upper respiratory tract. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application includes a request for the protection of proprietary data. 
The food that is the subject of the health claim is Yestimun
®
, which consists of (1,3)-(1,6)-β-D-
glucans from brewer’s yeast cell wall. The Panel considers that Yestimun® is sufficiently 
characterised. 
The claimed effect proposed by the applicant is related to the defence against pathogens in the upper 
respiratory tract. The target population proposed by the applicant is adults in the general population. 
The Panel considers that defence against pathogens in the upper respiratory tract is a beneficial 
physiological effect. 
The applicant performed a literature search in Medline for publications in English and German using 
keywords, “like yeast beta-glucan, immune system, oral, human, study, trial”. As directly pertinent to 
the claim, the applicant identified through the literature search one published randomised controlled 
trial (RCT) and provided two unpublished RCTs. 
These studies investigated the effect of Yestimun
®
 on the frequency of occurrence of common cold 
episodes or upper respiratory tract infections, on the duration of the infection and on symptom 
severity scores. 
The Panel notes that the evidence provided by the applicant does not establish the validity of the 
questionnaires and the criteria used in these studies to assess the incidence, duration or the severity of 
common cold episodes. The Panel also notes the limitations in the statistical analyses of these studies 
(e.g. exclusion of one study site from statistical analysis without appropriate justification and the 
requested re-analysis of the data was not presented for one of the studies, the multi-centre design was 
not taken into account in the statistical analyses of two of the studies and no account was taken for 
multiplicity of “primary outcomes” in one of the studies). 
The Panel considers that no conclusions can be drawn for the scientific substantiation of the claim 
from any of the human intervention studies provided by the applicant. 
The Panel notes that in the absence of an effect of Yestimun
®
 in humans on defence against pathogens 
in the upper respiratory tract the submitted human, animal and in vitro studies pertaining to a possible 
mechanism by which Yestimun
®
 could exert the claimed effect do not provide any scientific evidence 
for the substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Yestimun
®
 ((1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall) and defence 
against pathogens in the upper respiratory tract. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 20/08/2012. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence and includes a request for the protection of proprietary data. 
 On 04/10/2012, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 22/10/2012, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 25/10/2012. 
 On 14/12/2012, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 18/12/2012 and restarted on 02/01/2013, in compliance with Article 18(3) of 
Regulation (EC) No 1924/2006. 
 On 08/01/2013, EFSA received the requested information (which was made available to 
EFSA in electronic format on 07/01/2013). 
 During its meeting on 21/03/2013, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to Yestimun
®
 and 
defence against pathogens in the upper respiratory tract. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: Yestimun
®
 and defence against 
pathogens in the upper respiratory tract. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of Yestimun
®
, a positive assessment of its safety, nor a decision on whether Yestimun
®
 is, 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
Yestimun
®
 and defence against pathogens in the upper respiratory tract 
 
 
6 EFSA Journal 2013;11(4):3159 
INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Leiber GmbH, Hafenstraße 24, 49565 Bramsche, Germany. 
The application includes a request for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006 (manufacturing process). 
Food/constituent as stated by the applicant 
According to the applicant, the food, which is the subject of the claim, is Yestimun
®
, which is (1,3)-
(1,6)-β-D-glucan of brewer’s yeast cell wall (100 % Saccharomyces cerevisiae). 
Health relationship as claimed by the applicant 
According to the applicant, β-glucans of the yeast cell wall are dietary fibres that have been shown to 
induce immunostimulating responses in animals and humans after oral administration. Yestimun
®
 
causes a reduction of the number of common cold episodes during the cold season in normal subjects, 
which was shown in two independent studies. Common colds are caused by viruses, which are 
pathogens that are eliminated by the body’s defence mechanisms. The interaction of yeast β-glucan 
particles, like Yestimun
®, with the Peyer’s patches in the intestine alerts the immune system resulting 
in reduced numbers of common cold episodes and, thus, helps maintaining the body’s defence against 
pathogens. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Daily administration of 
Yestimun
®
 helps to maintain the body´s defence against pathogens”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, 0.45 g of Yestimun
®
 should be administered twice daily in order to obtain 
the claimed effect. The target population proposed by the applicant is adults in the general population. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is Yestimun
®
. 
Yestimun
®
 consists of (1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall (100 % Saccharomyces 
cerevisiae) (about 90 % by weight). β-Glucans are polysaccharides consisting of a backbone of 
D-glucose subunits linked by (1,3)-β-glucosidic bonds with irregular β-(1,6)-linked glucosidic side 
chains of various length. Information about the stability of the product, about the batch-to-batch 
variability of the (1,3)-(1,6)-β-D-glucan content in different batches of Yestimun® and about the 
manufacturing process has been provided by the applicant. β-Glucans are measureable in foods by 
established methods. 
The Panel considers that the food, Yestimun
®
 ((1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall), 
which is the subject of the health claim, is sufficiently characterised. 
Yestimun
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2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is related to the defence against pathogens in the upper 
respiratory tract. The target population proposed by the applicant is adults in the general population. 
The Panel considers that defence against pathogens in the upper respiratory tract is a beneficial 
physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in Medline for publications in English and German using 
keywords, “like yeast beta-glucan, immune system, oral, human, study, trial”. Studies were included if 
they used insoluble yeast β-glucans and investigated the incidence of common cold infections in 
humans or immunological parameters in animal and in ex vivo models. Exclusion criteria comprised 
studies using β-glucans other than S. cerevisiae-derived β-glucans and studies with parenteral 
administration. 
As directly pertinent to the claim, the applicant identified through the literature search one published 
randomised controlled trial (RCT) (Feldman et al., 2009) and provided two unpublished RCTs 
(Graubaum, 2007, unpublished; Bothe, 2011, unpublished). 
In the randomised, double-blind, placebo-controlled, seven-centre study by Bothe (2011, 
unpublished), 224 subjects (mean age: 46.0±15.7 years; 146 female) with recurrent upper respiratory 
tract infections were randomised to consume daily either 900 mg (2 x 450 mg) Yestimun
®
 (n=112) or 
placebo (maltodextrin, n=112) for 16 weeks (from October 2010 to May 2011). The primary endpoint 
of the study was the reduction in the number of common cold episodes per subject during the study 
period. Secondary outcomes were the severity of an entire common cold episode, the severity of an 
episode in the first two days, the severity of the episode at the “Episode Visit” (at the fifth day of each 
common cold episode), the duration of a cold episode and the use of antibiotics and analgesics. 
Subjects rated daily the severity of 10 pre-defined symptoms (headache, joint pain, sore throat, feeling 
of lump in the throat/difficulty swallowing, hoarseness, cough, running nose, nasal congestion, cold-
related sleeping difficulties, “fever” (not defined)) on a 4-level Likert item (symptom-free, mild, 
moderate and severe symptoms, except for “fever” which was always rated as severe) in diaries.  
A common cold episode was defined by the occurrence of at least two of the following symptoms 
rated at least as mild (2 on the 4-point item): sore throat, feeling of lump in the throat/difficulty 
swallowing, hoarseness, cough, running nose and nasal obstruction. Upon occurrence of a common 
cold episode, a composite score was calculated to assess the severity of the common cold episode.  
Following a request from EFSA to provide a rationale for the use of this questionnaire to assess the 
incidence, duration and severity of common cold episodes, the applicant referred to the Jackson 
criteria. These criteria include the rating of the following common cold symptoms on a 4-point item: 
sneezing, headache, malaise, chilliness, nasal discharge, nasal obstruction, sore throat and cough. A 
common cold episode is defined as a symptom score of 14 plus the subject’s subjective feeling of 
illness or increased nasal discharge on three out of six days. For symptom scores <14, both the 
subject’s subjective feeling of illness and an increased nasal discharge on three out of six days are 
required for diagnosis (Jackson et al., 1958). 
The Panel notes that both the questionnaire and the criteria used in the study by Bothe (2011, 
unpublished) to assess the incidence, duration and severity of common cold episodes differ from those 
developed by Jackson et al. (1958). The Panel considers that the evidence provided by the applicant 
does not establish the validity of the questionnaire and the criteria used in the study to assess the 
incidence, duration or the severity of common cold episodes.  
Yestimun
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Data were analysed by the Mann Whitney U test or by the χ2 test if proportions were analysed. In one 
study site, the average number of common cold episodes was statistically significantly different from 
the other study sites and lower than the expected number of common cold episodes per subject. Data 
from this study site (60 subjects) were removed from data analyses. Upon a request from EFSA to re-
analyse the data taking into account this study site, the applicant explained that this centre was 
excluded from analysis owing to possible underreporting of the outcome but did not provide the 
requested re-analysis of the data.  
The Panel notes that the evidence provided by the applicant does not establish the validity of the 
questionnaire and the criteria used in the study to assess the incidence, duration or the severity of 
common cold episodes. The Panel also notes that removing one centre from data analysis owing to 
possible underreporting which might have occurred in this site is not an appropriate justification for 
removing the site from the statistical analysis, that the results of the requested re-analysis of the data 
including this centre were not presented and that the statistical analysis did not account for the multi-
centre design of the study. The Panel considers that no conclusions can be drawn from this study for 
the scientific substantiation of the claim. 
In the randomised, double-blind, placebo-controlled, five-centre study by Graubaum (2007, 
unpublished), 100 healthy adult subjects (median age: 46.3 years, 58 women) with recurrent upper 
respiratory tract infections were randomised to consume daily either 900 mg (2 x 450 mg, n=50) 
Biolex
®
 Beta HP capsules (identical to Yestimun
®
) or placebo (micro-crystalline cellulose, n=50) for 
26 weeks (from November 2006 until June 2007). Doses of Biolex
®
 Beta HP or placebo had to be 
doubled upon occurrence of a common cold episode for the duration of the episode. The primary 
outcome of the study was the frequency of occurrence of common cold episodes. Secondary outcomes 
included the frequency of occurrence of individual common cold symptoms on the first day of the 
episode, severity of common cold symptoms expressed as composite common cold scores on days 1 to 
5 of the episode, relative changes in severity of common cold symptoms expressed as composite 
common cold scores from day 1 to day 3 and from day 1 to day 5, and the “therapeutic success” of 
doubling the dose of Biolex
®
 Beta HP or placebo upon occurrence of a common cold episode 
(=necessary intervention period until the first symptom free day of individual common cold 
symptoms). The Panel notes that for the present evaluation only outcomes related to the single dose of 
Biolex
®
 Beta HP were considered further and not those outcomes which were the target for treatment 
by doubling the dose of the intervention. 
Subjects rated daily the severity of six pre-defined symptoms (general feeling of illness, headache 
and/or joint pain, sore throat and/or difficulty in swallowing, hoarseness and/or coughing, watery 
nasal discharge and cold related sleeping difficulties) on a 3-level Likert item (no symptoms, mild 
symptoms, severe symptoms).  
A common cold episode was defined by the occurrence of at least one of the following symptoms: 
headache and/or joint pain; sore throat and/or difficulty swallowing; hoarseness and/or cough; 
rhinorrhoea; cold related sleep difficulty. Upon occurrence of a common cold episode, subjects also 
had to present themselves to the investigator, who documented the symptoms experienced by subjects 
at the beginning of the episode and five days thereafter. A composite score was calculated to assess 
the severity of the common cold episode. 
As for the study by Bothe (2011, unpublished), the Panel considers that the evidence provided by the 
applicant does not establish the validity of the questionnaire and the criteria used in the study to 
assess the incidence or the severity of common cold episodes.  
Data were analysed using the Mann-Whitney U test. The χ2 test was used when proportions were 
analysed. A non-parametric, multivariate analysis for repeated measures was used in the longitudinal 
analysis of secondary outcomes. Post-hoc analyses were performed based on episodes that occurred in 
the winter months (November to March, first half of the study) to avoid error that might have arisen 
Yestimun
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owing to possible misdiagnosis of allergic rhinitis as common cold infections during the summer 
months.  
The Panel notes that the evidence provided by the applicant does not establish the validity of the 
questionnaire and the criteria used in the study to assess the incidence or the severity of common cold 
episodes. The Panel also notes that the statistical analysis did not account for the multi-centre design 
of the study and that avoidance of possible misdiagnosis is not an appropriate justification for 
conducing post-hoc analyses. The Panel considers that no conclusions can be drawn from this study 
for the scientific substantiation of the claim.  
A double-blind, placebo-controlled, randomised intervention (Feldman et al., 2009) in 40 healthy 
adults investigated the effects of consuming 500 mg/day Wellmune
®
 (70 % yeast beta-glucan; n=21) 
for 90 days vs. placebo (rice flour; n=19) on symptomatic respiratory tract infections. Upon 
occurrence of a respiratory symptom, subjects were asked to present themselves to the investigators 
for diagnosis and were provided with symptom diaries. No information was provided about the 
criteria used in the diagnosis of respiratory tract infections or about the symptom diaries used. 
Endpoints included the number of, and total days with, symptomatic respiratory tract infections 
(defined as common cold, influenza, pharyngitis), the average duration of a symptomatic respiratory 
tract infection, symptom severity of 13 pre-defined symptoms, and the number of missed school/work 
days. A total of 12 subjects dropped out from the study. Changes from baseline were analysed using 
repeated measures analysis of variance (RM-ANOVA) without correcting for multiple comparisons 
made. 
The Panel notes that the criteria used to diagnose respiratory tract infections are unclear and that 
information about the symptom diaries used in the study is missing. The Panel also notes the small 
sample size of the study, the high drop-out rate and that the statistical analysis did not take into 
account the multiplicity of “primary outcomes”. The Panel considers that no conclusions can be 
drawn from this study for the scientific substantiation of the claim.  
The Panel notes that no human intervention studies from which conclusions could be drawn for the 
scientific substantiation of the claim were provided by the applicant. 
With respect to the potential mechanism by which Yestimun
®
 could exert the claimed effect the 
applicant provided two human studies (Döll et al., 2005; Lehne et al., 2006), seven animal studies 
(Fleischer et al., 2000; Fleischer et al., 2001; Vetvicka et al., 2002; Hong et al., 2004; Li et al., 2005; 
Małaczewska et al., 2010; Wójcik, 2010), four in vitro studies (Seljelid et al., 1981; Sandula et al., 
1995; Kankkunen et al., 2010; Goodridge et al., 2011) and seven review publications (Bohn and 
BeMiller, 1995; Kogan, 2000; Tzianabos, 2000; Brown and Gordon, 2005; Zekovic et al., 2005; 
Akramiene et al., 2007; Volman et al., 2008).  
The Panel notes that in the absence of an effect of Yestimun
®
 in humans on defence against pathogens 
in the upper respiratory tract the submitted human, animal and in vitro studies pertaining to a possible 
mechanism by which Yestimun
®
 could exert the claimed effect do not provide any scientific evidence 
for the substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Yestimun
®
 ((1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall) and defence 
against pathogens in the upper respiratory tract. 
Yestimun
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CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, Yestimun® ((1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall) which is the 
subject of the health claim, is sufficiently characterised. 
 The claimed effect proposed by the applicant is related to the defence against pathogens in the 
upper respiratory tract. The target population proposed by the applicant is adults in the 
general population. Defence against pathogens in the upper respiratory tract is a beneficial 
physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
Yestimun
®
 ((1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall) and defence against 
pathogens in the upper respiratory tract. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on Yestimun
®
 and defence against pathogens in the upper respiratory tract 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0364_DE). October 
2012. Submitted by Leiber GmbH. 
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GLOSSARY AND ABBREVIATIONS 
RM-ANOVA Repeated measures analysis of variance 
RCT Randomised controlled trial 
